Ainos, Inc. (NASDAQ:AIMD) Sees Significant Decrease in Short Interest

28 Jun 2026, 15:00 by Michael Walen · The Markets Daily

Ainos, Inc. (NASDAQ:AIMD – Get Free Report) saw a large decrease in short interest in the month of June. As of June 15th, there was short interest totaling 18,552 shares, a decrease of 79.8% from the May 31st total of 91,823 shares. Based on an average daily volume of 66,646 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.2% of the company’s shares are sold short.

Ainos Trading Down 3.9%

Shares of AIMD traded down $0.07 during mid-day trading on Friday, reaching $1.73. The company had a trading volume of 22,117 shares, compared to its average volume of 66,730. Ainos has a fifty-two week low of $1.26 and a fifty-two week high of $4.50. The firm has a fifty day simple moving average of $1.90 and a 200-day simple moving average of $1.79. The stock has a market cap of $14.74 million, a price-to-earnings ratio of -0.60 and a beta of 2.41. The company has a current ratio of 0.55, a quick ratio of 0.50 and a debt-to-equity ratio of 1.58.

Ainos (NASDAQ:AIMD – Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($0.41) earnings per share for the quarter. Ainos had a negative return on equity of 160.55% and a negative net margin of 11,912.10%.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, May 26th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Ainos currently has a consensus rating of “Sell”.

Check Out Our Latest Stock Analysis on AIMD

Insider Transactions at Ainos

In other news, Director Chun-Jung Tsai sold 27,718 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $1.87, for a total transaction of $51,832.66. Following the sale, the director owned 658,199 shares in the company, valued at $1,230,832.13. This trade represents a 4.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ting-Chuan Lee sold 109,988 shares of Ainos stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $1.90, for a total value of $208,977.20. Following the completion of the sale, the director directly owned 807,417 shares of the company’s stock, valued at approximately $1,534,092.30. This represents a 11.99% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have acquired 7,800 shares of company stock worth $15,946 and have sold 179,788 shares worth $359,247. Insiders own 9.79% of the company’s stock.

Hedge Funds Weigh In On Ainos

A number of large investors have recently modified their holdings of the company. Mariner LLC acquired a new position in shares of Ainos in the 4th quarter valued at about $37,000. Two Sigma Investments LP purchased a new position in Ainos in the third quarter valued at approximately $80,000. DRW Securities LLC lifted its position in Ainos by 272.6% during the fourth quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock valued at $109,000 after buying an additional 48,439 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in Ainos by 13.1% during the fourth quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock valued at $109,000 after buying an additional 7,700 shares in the last quarter.

Ainos Company Profile

(Get Free Report)

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.